上海和誉生物医药科技有限公司（AbbiskoTherapeutics）位于上海张江科学城，是一家从事小分子新药研发的创新研发型企业。公司致力于造福病患，专注于国内国际尚无有效治疗手段的疾病领域的新药研发。公司创始人及管理团队由多位国家“千人计划”和资深专家组成，拥有多年国际国内大型药企研发管理经验，曾主导和参与了多个临床及上市新药的研发。成立四年来，公司已有多个自主研发新药项目进入或即将进入临床试验。
Location: China, Shanghai
Employees: 51-200
Total raised: $193M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Lake Bleu ... | lakebleu-c... |
| - | The Carlyl... | carlyle.co... |
| - | Qiming Ven... | qimingvent... |
| - | Loyal Vall... | loyalvalle... |
| - | Qiming Ven... | qimingvc.c... |
| - | Warburg Pi... | warburgpin... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.01.2021 | Series D | $123M | The Carlyl... |
| 25.03.2019 | - | $42M | Qiming Ven... |
| 08.02.2017 | - | $28M | - |
Mentions in press and media 24
| Date | Title | Description |
| 19.09.2024 | Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC | SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety... |
| 28.06.2024 | 50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress | SHANGHAI, June 28, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atez... |
| 09.01.2024 | Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021） | SHANGHAI, Jan. 9, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（O... |
| 04.12.2023 | Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck | SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms o... |
| 02.03.2023 | Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376 | SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shan... |
| 30.01.2023 | Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021） | SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA... |
| 18.01.2023 | Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD | SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been approved by the National Medical Products Adminis... |
| 04.07.2022 | Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 | SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial... |
| 14.12.2021 | Carlyle : Raises Nearly $8 Billion for Ninth U.S. Real Estate Fund | Washington, DC - Global investment firm Carlyle (NASDAQ: CG) today announced that it has raised approximately $8 billion for its ninth U.S. real estate opportunity fund, Carlyle Realty Partners IX (CRP IX), exceeding its $6 billion initial ... |
| 09.01.2021 | Reuters: Chinese biotech firm Abbisko raises $123 million in Ser D | - |
Show more